Foreign institutional investors (FIIs) have shown increased interest in the Indian pharmaceutical sector, as evidenced by their growth in stakes for companies like Shilpa Medicare, Marksans Pharma, and Jagsonpal Pharma during Q1 FY26. Notably, Shilpa Medicare is expanding its presence in Latin America, Marksans Pharma has secured FDA approvals, while Jagsonpal Pharma focuses on women's health and maintaining financial discipline.

Axis Securities suggests investors consider Voltamp Transformers, Shilpa Medicare, and Persistent Systems as potential buys. Despite crude price worries, both Nifty 50 and Sensex experienced slight growth on April 2, with Nifty rising by 0.15% to 22,713.1 and Sensex increasing by 0.25% to 73,319.55.